Immunovant Abandons Batoclimab for IMVT-1402 in Myasthenia Gravis and CIDP
Immunovant has opted not to pursue commercialization of its FcRn inhibitor batoclimab for myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP), citing concerns over its impact on cholesterol levels. The biotech had previously made a second-generation molecule, IMVT-1402, its lead candidate in both indications. A phase 3 trial of batoclimab hit its primary endpoint in … Read more